American Heart Association

UNMC College of Medicine received over $7 million in new funding in September, with grants awarded to various faculty members for studies ranging from cardiovascular disease diagnosis to HIV/SIV reservoirs and COVID-19 eye studies, among others.

The FDA approved Johnson & Johnson’s Varipulse PFA Platform for drug-resistant paroxysmal AFib, featuring PFA therapy with the CARTO 3 system for ablation accuracy. The admIRE study showed 100% procedural success, 98% first-pass isolation, and 85% peak primary effectiveness. The platform integrates with CARTO 3 for efficient, fluoroscopy-free procedures, addressing the growing prevalence of AFib.

Dr. Pedro Martinez-Clark, a Harvard-trained cardiologist, partners with LimFlow® to offer the FDA-approved LimFlow® System for chronic limb-threatening ischemia (CLTI), aiming to prevent amputations and improve patient quality of life. The system, based on the PROMISE II trial, shows 76% of 'no-option' CLTI patients avoided amputation and experienced significant wound healing and pain relief.

Rocket Pharmaceuticals reports Q3 2024 financial and operational results, including completion of enrollment in RP-A501 Phase 2 pivotal study for Danon disease, initiation of rolling BLA submission for RP-L102 for Fanconi Anemia, and appointment of Mikael Dolsten to the Board of Directors. The company anticipates FDA approval for KRESLADI for severe LAD-I in 2025 and expects its cash, cash equivalents, and investments to fund operations into 2026.

Virginia J. Howard, Ph.D., FAHA, distinguished professor at UAB, will receive the 2024 Population Research Prize at the American Heart Association's Scientific Sessions 2024. Her research focuses on stroke disparities, cognitive functioning, and stroke risk factors, particularly in the REGARDS study. Dr. Howard's work has significantly contributed to stroke prevention and treatment, emphasizing early life factors, sex, race, and geographic location.

Article references on heart failure epidemiology, sex differences in etiology and burden, inclusion of women in clinical trials, improving trial representativeness, global mortality variations, factors associated with non-use of medical therapy, AHA/ACC/HFSA guidelines, ESC guidelines, rapid evidence-based sequencing of foundational drugs, safety and efficacy of up-titration of guideline-directed medical therapies, bridging treatment implementation gaps, pharmacological treatment of heart failure with reduced ejection fraction, collection of race and ethnicity data in clinical trials, factors associated with racial and ethnic diversity among trial participants, lesser response to ACE inhibitor therapy in black patients, efficacy of angiotensin-converting enzyme inhibition, efficacy of angiotensin-receptor blockers, efficacy of SGLT2 inhibitors, regional and ethnic influences on response to empagliflozin, efficacy of dapagliflozin in black versus white patients, lifetime risk for heart failure among white and black Americans, sex- and age-related differences in management and outcomes, sex disparities in longitudinal use of medical therapy, effects of empagliflozin on cardiovascular and renal outcomes according to age, MRAs in elderly HF patients, efficacy and safety of LCZ696 according to age, efficacy and safety of dapagliflozin according to age, effect of age and sex on efficacy and tolerability of beta blockers, effect of nebivolol on mortality in elderly patients, safety and efficacy of up-titration of medical therapies in elderly patients, vericiguat in patients with heart failure, cardiac myosin activation with omecamtiv mecarbil, trial characteristics associated with under-enrolment of females, NIH policy on inclusion of women and minorities, FDA guideline for study and evaluation of gender differences, EMA gender considerations in clinical trials, Tri-Council Policy Statement on ethical conduct for research involving humans, heart failure with preserved ejection fraction, evaluation of causes of sex disparity in heart failure trials, inclusion of pregnant and lactating women in clinical trials, eligibility criteria of randomized controlled trials, gender paradox in congestive heart failure, sex differences in willingness to participate in clinical trials, women's participation in cardiovascular clinical trials, interactions between left ventricular ejection fraction and sex, sex-specific differences in efficacy of heart failure therapies, sex-based differences in effect of digoxin, sex-specific differences in heart failure pathophysiology, risk factors, management, and outcomes, identifying optimal doses of heart failure medications, sex-specific analysis of up-titration of medical therapies, age, sex, and outcomes in heart failure with reduced EF, impact of socioeconomic status on incident heart failure and left ventricular dysfunction, heart failure and socioeconomic status inequality, associations of healthy lifestyle and socioeconomic status with mortality and incident cardiovascular disease, socioeconomic status and cardiovascular outcomes, lower socioeconomic status predicting higher mortality and morbidity in heart failure patients, trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis, association between socioeconomic status, sex, race/ethnicity and in-hospital mortality, risks of subgroup-specific analyses in randomized trials.

Lehigh Valley Health Network (LVHN) invites RNs to a virtual recruitment event on Nov 20th, 2-6 PM, offering positions in Med/Surg, Emergency Medicine, ICU, Perioperative, and PCU units with competitive benefits and up to $30,000 sign-on bonuses. LVHN, a Magnet Hospital, has been ranked among the 'Best Hospitals' for 23 consecutive years and received 'A' grades for patient safety.

The global induced pluripotent stem cells (iPSCs) market, valued at USD 1.88 billion in 2023, is projected to grow to USD 4.48 billion by 2032, driven by advancements in regenerative and personalized medicine, drug discovery, and increased investments in stem cell research. Key market participants focus on improving iPSC generation methods, while challenges include high production costs, ethical issues, and regulatory complexities. North America leads the market, with Asia-Pacific showing rapid growth.

Higher resting heart rate linked to increased risk of atrial fibrillation in Black adults, with every 10-bpm increase associated with a 9% higher risk, according to a study in JAMA Network Open. This is the first study to focus on A-fib risk among Black patients, highlighting the need for further research on resting heart rate as a screening tool.

Studies highlight temporal trends in cardiogenic shock epidemiology, management, and outcomes, with focus on inflammation, biomarkers, and interleukin-6 receptor inhibition in acute myocardial infarction and COVID-19.